# Diabetes Research Hub — Daily Iteration Report

**Date:** 2026-08-11 (Tuesday)
**Run type:** Automated scheduled iteration (state-aware). Not Monday → no weekly PubMed sweep (yesterday's Monday sweep is current).

## Summary

Processed 4 substantive work-queue items plus the mandatory credibility sweep and an offline pipeline rebuild. No fabricated data, no claim drift, no tier changes. Corpus unchanged at **287 papers (274 VETTED / 13 FLAGGED / 0 UNVETTED)**.

## Work completed

**1. Credibility sweep (every run) — CLEAN**
Grep across all `Analysis/Scripts/*.py`: no fabricated PMIDs (≥42,000,000), no "zero SAEs" / "zero rejection", no "curative"/"achieves-cure" language. The only "curative" matches are inside `verify_before_deploy.py`, which is the detector itself (expected).

**2. Paper vetting batch — 15 oldest re-checked, NO drift**
Re-verified the 15 VETTED papers with the oldest `last_checked` (2026-04-20/21). Every PMID resolves in `paper_library/index` with a matching abstract; spot-checked titles/journals (e.g. PMID 24838679 *Autoantibodies and type 1 diabetes* — Diabetologia 2014; PMID 25587654 *JAK-STAT pathway* — Annu Rev Med 2015; PMID 25498346 *berberine meta-analysis* — J Ethnopharmacol 2015) match the state exactly. No claim drift. `last_checked` advanced to 2026-08-11.

**3. Path validation — teplizumab long-term follow-up → REAFFIRMED VALIDATED (HIGH)**
Web-searched durability evidence. Added a new confirming data point: **TN-10 Extension** (ADA 2025 abstract *db25-840-P*, DOI 10.2337/db25-840-P), which followed former TN-10 participants who progressed to Stage 3 — reaffirming the delay-of-progression signal. The **PROTECT Extension** (NCT04598893) is an observational, no-drug long-term safety/durability study, ongoing. C-peptide preservation is solid at years 1–2 (one or two courses); **durability beyond 2 years remains an open question** per 2025–26 reviews. Status held VALIDATED (HIGH) for 0–2 yr; long-term durability flagged as partially-established/open. Existing external PMIDs unchanged (31180194, 37865119/37889505, 39949173).

**4. Gap audit — Gap #10 (LADA prevalence by healthcare setting, SILVER, promotion candidate) → REMAINS SILVER**
Searched for a setting-segmented (primary-care vs specialist) LADA prevalence SR/MA published since the 2026-07-30 audit. Still none. New hits are narrative/clinical-guidance only (AAFP LADA recognition blog; Cleveland Clinic J Med 92(12):757, 2025; DiabetesOnTheNet primary-care review) plus the earlier primary-care risk score (PMC9910627) and cross-sectional prevalence (PMC9270809). The 2023 worldwide SR&MA (pooled 8.9%, 95% CI 7.5–10.4) remains strongest. **SILVER→GOLD promotion not yet justified** — the defining claim (setting-dependent prevalence differential) still lacks a dedicated meta-analysis. Retained SILVER, promotion_candidate=true; next audit ~2026-09-10.

**5. Pipeline rebuild (offline) — CLEAN**
`run_quality_improvements.py`: **24/24 offline build/dashboard scripts completed [OK] with zero errors.** The run stalls at the *"Verifying PMIDs against PubMed API"* stage — a network stage the sandbox cannot reach reliably. Per existing queue item, the network stages (`pmidverify`, `ingest`, `validate-citations`) are deferred to the local machine.

## State & queue
- State saved; backup `agent_state.json.bak_2026-08-11` written (640 KB).
- `run_history` now 118 entries; `last_run` = 2026-08-11.
- Queue reprioritized: teplizumab path (next ~2026-09-11), Gap #10 (next ~2026-09-10), paper-vetting batch advanced to next-oldest cohort, network-stage rebuild flagged for local run.

## Action required by user (unchanged, persistent)
**Git push is blocked in the sandbox** (no GitHub auth; OneDrive lock-file protection). All research changes are saved to working files on disk regardless. From local PowerShell at `C:\Users\justi\OneDrive\Diabetes_Research`:
```
Remove-Item .git\*.lock -ErrorAction SilentlyContinue
git add -A; git commit -m "Daily iteration 2026-08-11"; git push
```
Also run the network stages locally: `python Analysis/Scripts/run_quality_improvements.py` (completes `pmidverify`/`ingest`/`validate` with PubMed access).

## Constraints honored
No fabricated PMIDs/citations/data. No overstated preclinical claims. All claims trace to a source. Research synthesis only — not medical advice.
